HIV Drugs Market

Premium Insights

The global HIV Drugs Market is valued at USD 34.75 Billlion in 2024 and is projected to reach a value of USD 56.5 Billlion by 2035 at a CAGR (Compound Annual Growth Rate) of 4.55% between 2025 and 2035.

The management of HIV/AIDS normally includes the usage of multiple antiretroviral drugs as a strategy to control HIV infections. Several antiretroviral agents act on different stages of the HIV life cycle. The utilization of multiple drugs that can act on different viral targets is known as highly active antiretroviral therapy (HAART). The global HIV Drugs market is expected to grow significantly during the forecast period owing to the rising prevalence of HIV diseases worldwide combined with the rising rate of treatment. Additionally, increasing government activities for raising awareness among people about HIV causes and symptoms, along with rising treatment options, will add to sustainable market growth.

Rising awareness among the general population is expected to play a crucial role in the sales of HIV Drugs. The forecast period will be rife with the increasing prevalence of unprotected sex, contaminated needles or syringes, and a lack of awareness regarding transmission is expected to cause a surge in the growth of the global HIV Drugs market. Additionally, factors driving the growth of the HIV Drugs market are rising concerted efforts of various governments and NGOs to provide at-risk individuals with greater access to disease testing and treatment for infected people. Moreover, the inclusion of generic drugs at a cost-effective, which have been available in a chemically induced form similar to branded drugs, will add to the market demand.

The increasing patient population combined with the rising product launched is further likely to fuel the global market growth. A significant amount of the revenue generated is processed toward research and development. This led to the introduction of new products to the existing portfolio. The forecast period is also expected to increase the promotion of government-run awareness programs. These factors are expected to increase the market penetration rate within developing economies. Many prominent players are focused on strategic collaborations by launching new medications globally. For instance, in September 2019, Merck Sharp & Dohme Corp, Merck & Co., Inc. subsidiary, received their U.S FDA approval for PIFELTRO and DELSTRIGO.

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2019, there were approximately 2.2 million individuals living with HIV in western and Central Europe. More than 20.7 million people in North America live with HIV/AIDS. A larger consumer pool is expected to fuel the growth of the market. However, lack of treatment and unawareness of HIV infections, combined with the fact that there is no cure for this infection, will restrain the growth of the global HIV Drugs market during the forecast period. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), there is an uneven distribution of treatment options globally.

Economic Insights

Based on various probability models, several financial experts have forecast that the US will likely enter a recession over the next 12 months. This forecast is based on the federal rate increase implemented by the government to combat inflation and rising prices. It is anticipated that the final quarter of 2022 and the first quarter of 2023 will show negative GDP growth rates, indicating the onset of a recessive situation. The aggression war waged by Russia on Ukraine is still having a significant negative impact on the world economy. Due to several issues, including rising energy prices, inflationary pressure, declining confidence, and declining household spending power, the global economy is predicted to slow considerably in the next few years.

Top Market Trends

1. Rising R&D Initiatives for Developing Long-Acting Suppressive Antiretroviral Therapy: An ongoing trend of developing antiretroviral therapy as long-acting suppression (ATLAS) and the first long-acting injectable formulations are expected to provide a convenient treatment option. These treatment options are expected to be administered once a month. Studies have indicated an ongoing increase in the patient pool, enabling physicians to anticipate an increase in compliance rate for adoption.

2. Changing Pattern of Drug Administration: For decades, there was a systematic drug delivery of antiretrovirals used to treat HIV/AIDS. However, the new complete long-acting regime combines cabotegravir and rilpivirine, which are growing in popularity as an alternative for the existing dosage. The new injectable formula has entered the global market and further increased the standard of care compared to the most prescribed HIV Drugs. The new treatment will reduce the dosing days from 365 days to 12 days per year.

3. Increasing Number of Product Launches: The global product HIV Drugs market is dominated by a handful of players dominating the maximum share. Numerous drug innovations have taken place within the last few years. The prominent players focus on strategic collaborations and launching new products launches globally. For instance, in February 2018, Mylan Inc. announced the launch of Efavirenz tablets in the US. Efavirenz tablets are the first generically available version of Sustiva. This product is expected to be given in combination with other retroviral agents for treating type 1 HIV infections in adults and paediatric patients.

4. Growing Consumer Base: According to the World Health Organization (WHO), an estimated 33.0 million people were living with HIV infections, with more than 1.7 million cases reported in 2019. This huge patient population across various regions creates an intense demand for antiretroviral (ARV) drugs.

5. Awareness Among Consumers: Studies have indicated that people are becoming increasingly aware of HIV and its occurrences. This has led to an increase in testing processes. This has led to rising demand for HIV Drugs and further management and treatment of the disease. Increasing efforts by various government organizations among emerging economies are expected to widen the markets scope. For instance, the National AIDS Control Program (NACP), formed in 1992, is considered Indias comprehensive HIV/AIDS drugs prevention and control program.

Market Segmentation

The global HIV Drugs market can be categorized on the following: Drug Class, Distribution Channel, and Regions. By drug class, the market can be segmented across integrase inhibitors, non-nucleoside reverse transcriptase inhibitors (NRTIs), combination HIV medicines, and others. In terms of distribution channel, the market can be fragmented across hospital pharmacies, retail pharmacies, online pharmacies, and others. Likewise, based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on Drug Class

Combinative HIV Medicines to Dominate Market Share Owing to Rising Demand Due to Better Results

The combinative HIV medicines are expected to occupy the largest market share in revenue and growth. Factors such as the rising demand for combinative HIV medicines owing to better results in managing HIV and other co-related infections combined with the most technological developments within the drug class will increase the footprint of the segmental growth. Rising adoption of this medication will also rise owing to better results in controlling the spread of HIV and other co-infections. Combinative HIV medicines offer ease of consumption, and adherence will further project sustainability. Integrase inhibitors will grow with the fastest growing CAGR during the forecast period because the drug class is the first defense class for treating AIDS.

Based on Distribution Channel

Hospital Pharmacies to Occupy Largest Market Share While Retail Pharmacies to Grow with the Fastest Growing CAGR

Hospital pharmacies are expected to dominate the global HIV Drugs market due to rising hospital patient visits and sales of prescribed antiretroviral drugs. Additionally, an increasing number of patients who have HIV and a lower focus on sex education on a global scale are expected to add to the segmental growth during the forecast period. Also, hospital pharmacies contain a wide range of drugs that can treat various degrees of the human immunodeficiency virus. These factors are expected to increase the growth of hospital pharmacies during the forecast period. Retail pharmacies are expected to grow with the fastest growing CAGR during the forecast period owing to a higher preference for buying oral drugs from these locations.

Based on Region

North America to Register Largest Market Share Owing to Rising Prevalence of HIV Among the General Population

The global HIV Drugs market is expected to be driven by the North American region in terms of market share and revenue. Factors such as the increasing prevalence of HIV infections among the US population and rising awareness about treatment options will contribute to sustainable market growth.

Europe is expected to occupy the second-largest market share in terms of growth owing to rising cases of HIV infections combined with a large number of HIV companies. Rising strategic collaborations amongst the European players have led to improved drug availability. This is expected to increase the viability of the European HIV Drugs market.

Competitive Landscape

The global HIV Drugs industry is expected to be highly competitive due to the presence of prominent market players. These players are expected to create a competitive level through the rising sales of antiretroviral drugs with new product launches. Additionally, these players are focused on strategic collaborations to enlarge the consumer base for their product portfolios.

The key players in the global HIV Drugs market include - ViiV Healthcare (U.S.) among others.

Recent Market Developments:

· July 2021: Unitaid and Clinton Health Access Initiatives, Inc. announced a pricing agreement with pharma company Hetero Labs LTD to provide darunavir combined with ritonavir (DRV/r) as a second line-therapy for HIV patients. This pricing agreement aims to increase the product range to consumers in low and middle-income countries at a rate of USD 210 per patient/year.

· March 2021: Gilead Sciences Inc and Merck announced a collaboration agreement for developing and commercializing long-active treatment for HIV. The collaboration plans to combine Gileads investigational capsid inhibitor lenacapvir and Mercks investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, to develop a two-drug regime for HIV.

· January 2021: ViiV Healthcare received U.S. FDA approval for Cabenuva, an injectable drug for treating human immunodeficiency virus type I (HIV) infections in adults.

Segmentation of the Global HIV Drugs Market